Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$11.35M-$11.35MN/M vs Q3 2024 EPS Diluted-$1.03-$1.03N/M vs Q3 2024 Operating Income-$10,177,000N/M Operating Cash Flowderived-$7,878,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end